# CUREfilm® D

**50,000 IU of Vitamin D3 (Cholecalciferol) delivered with an innovative oral thin film platform as a once-weekly high potency supplement.**

CUREfilm® D is classified in the United States as a dietary supplement to be dispensed under direct clinical supervision. In other countries, CUREfilm® D may be classified as a medication.

Administration of cholecalciferol as an oral thin film (OTF) has the following advantages:

- Precise dosing compared to liquid formulations.
- No water required compared to tablets.
- No chewing required compared to wafers.
- No risk of choking.
- Microencapsulation (in the OTF) improves bioavailability.[1]



**SUPPLEMENT FACTS**

Serving Size: 1 oral film — Servings per Container: 1

| | Amount Per Serving | % Daily Value |
|---|---|---|
| Vitamin D3 (as cholecalciferol) | 50,000IU | 8333% |

**Other ingredients:** Sodium Carboxymethyl Cellulose, Natural and Artificial Flavors, Polyvinylpyrrolidone K90, Microcrystalline Cellulose, Vitamin E (antioxidant), Glycerin, Water, Polysorbate 80, Cocoa Butter, Sucralose, Ascorbyl Palmitate, FD&C Red 40.

**Manufactured by:**
CURE Pharmaceutical
1620 Beacon Place,
Oxnard, CA 93033
(877) 765-1909

**SUGGESTED USE:**
Take one oral film once weekly under direct clinical supervision. Place one strip on tongue. Let dissolve and swallow.

**FOR ADULT USE ONLY.**
**KEEP OUT OF REACH OF CHILDREN**

**WARNING:**
Consult your physician before using this supplement. Do not use this supplement for more than 90 days without consulting your physician.

Natural color variation may occur.
Store in cool, dry place.

(59°-77°F/15°-25°C)
Refrigerate if possible.

CUREinside™




## Contact Us

**CURE Pharmaceutical**
(805) 824-0410
info@curepharma.com
www.curepharma.com

## CURE Pharmaceutical At a Glance

**Sector**
Drug delivery, Pharmaceuticals, Wellness

**Date Founded**
July 2011

**Products & Services**
- CUREform drug delivery platform
- Research and manufacturing services

**Intellectual Property**
- 14 U.S. issued patents
- 1 China issued patent
- 23 pending applications
- Proprietary equipment design

**Development Stage**
Growth

**Number of Employees**
25

# CUREfilm® D Case Study Data

**STUDY:**
Clinical case studies evaluating 25-hydroxyvitamin D levels in patient serum under fasting conditions after 12 weekly treatments.

**STUDY DRUG:**
1.25mg Cholecalciferol CUREfilm D (equivalent to 50K IU Vitamin D3).

**RESULT**:
CUREfilm D was effective at increasing 25-hydroxyvitamin D in patient blood.

| Patient | Age | Gender | Pre treatment 25-hydroxyvitamin D levels | 12-week post treatment 25-hydroxyvitamin D levels | Delta |
|---|---|---|---|---|---|
| 1 | 35 | Male | 32.9 ng/ml | 58.7 ng/ml | 25.8 ng/ml (+78%) |
| 2 | 63 | Male | 28 ng/ml | 95.8 ng/ml | 67.8 ng/ml (+242%) |
| 3 | 55 | Male | 35.4 ng/ml | 50.9 ng/ml | 15.5 ng/ml (+44%) |
| 4 | 60 | Female | 31.5 ng/ml | 78.9 ng/ml | 47.4 ng/ml (+150%) |

*CUREfilm® D is an oral thin film with a pleasant berry flavor. Film size is approximately 1.5 x 0.5 inches (38 x 12 mm).*

*Photographs are not to scale.*

# Published Studies on the Effects of Vitamin D Supplementation on Risk of Acute Respiratory Tract Infection

*BMJ (British Medical Journal)*

**Systematic review and meta-analysis of individual participant data from randomized controlled trials.** [2]

- Vitamin D supplementation resulted in a statistically significant reduction in the proportion of participants experiencing at least one acute respiratory tract infection and statistically significant protective effects of vitamin D for acute respiratory tract infection rate
- This evidence was assessed as being of high quality
- Daily or weekly vitamin D treatment was associated with an even greater degree of protection against acute respiratory tract infections at all blood levels
- Protective effects of daily or weekly vitamin D supplementation were statistically significantly greater in the subgroup of participants with profound vitamin D deficiency.

Click to read the study

*Fox News: Opinion*

**Former CDC Chief Dr. Tom Frieden: Coronavirus infection risk may be reduced by Vitamin D.** [3]

- Vitamin D supplementation reduces the risk of respiratory infection, regulates cytokine production and can limit the risk of other viruses such as influenza.
- A respiratory infection can result in cytokine storms – a vicious cycle in which our inflammatory cells damage organs throughout the body – which increase mortality for those with COVID-19.
- Adequate Vitamin D may potentially provide some modest protection for vulnerable populations.
- Given the high prevalence of Vitamin D deficiency in this country, it is safe to recommend that people get the proper daily dosage of Vitamin D.

Click to read the article

*Health Technology Assessment*

**Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis.** [4]

- Vitamin D supplements reduced the risk of having at least one ARI from 42% to 39%.
- Vitamin D had greater protective effects when it was given daily or weekly to people with the lowest vitamin D levels: the risk of having at least one ARI was reduced from 60% to 32% in these individuals.
- Vitamin D was not effective in protecting against ARIs when it was given in large, widely spaced doses.
- Taking vitamin D supplements was found to be safe.

Click to read the study

*SmilePage Health Institute*

**A COVID-19 "Perfect Storm" Demands Immediate CDC Action to Treat the Long Ignored Global Pandemic of Vitamin D Deficiency.** [5]

- Around 70% to 80% of people have Vitamin D Deficiency (VDD).
- VDD increases the risk and/or promotes over 300 illnesses and infections which can kill–maybe including COVID-19.
- Vitamin D is critical to having a good immune system for better overall health, less disease and longer life.
- Vitamin D can boost the immune system, fight infection and kill bacteria, kill funguses and kill viruses.
- Research shows VDD increases the risks of many diseases including infectious diseases like: Epidemic Flu, Annual Flu, Influenza Flu Virus and Respiratory Infections, Lung Infections, Tuberculosis (TB), Pneumonia, and Intensive Care Unit (ICU) Sepsis Related Mortality

Click to read the study

# About Powered By CURE™

CUREfilm® D is marked with the Powered by CURE™ Mark of Quality.

All CURE Pharmaceutical's products bear this mark as an indication of the proven efficacy and bioavailabilty of the patented technologies that power our products.

## References


1. Šimoliūnas, E., Rinkūnaitė, I., Bukelskienė, Ž., & Bukelskienė, V. **"Bioavailability of Different Vitamin D Oral Supplements in Laboratory Animal Model."** *Medicina (Kaunas, Lithuania)* 2019 Jun, 55(6), 265. doi: https://doi.org/10.3390/medicina55060265

2. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman Peter, et al. **"Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data."** *BMJ* 2017 Feb; 356 doi: https://doi.org/10.1136/bmj.i6583

3. Frieden, T. **"Opinion: Former CDC Chief Dr. Tom Frieden: Coronavirus infection risk may be reduced by Vitamin D."** published Mar 23, 2020. Retrieved from foxnews.com

4. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, et al. **"Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis."** *Health technology assessment (Winchester, England)* 2019 Jan, 23,2): 1-44. doi: https://doi.org/10.3310/hta23020

5. Page, D, **"A COVID-19 "Perfect Storm" Demands Immediate CDC Action to Treat the Long Ignored Global Pandemic of Vitamin D Deficiency."** *PR Newswire Press Release*, published Feb 25, 2020. Retrieved from ptcommunity.com


## Contact Us


**CURE Pharmaceutical**
1620 Beacon Place
Oxnard, CA 93033
(805) 824-0410
info@curepharma.com
www.curepharma.com